Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with histologically confirmed diagnosis of ulcerative colitis in remission
1 finding from 1 review
Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics may leads to higher total adverse events (6 months) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (Rachmilewitz index) (14 days) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
Withdrawals due to adverse events · people with histologically confirmed diagnosis of ulcerative colitis in remission
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Infant hospitalisation with laboratory‐confirmed RSV disease · pregnant women
Respiratory syncytial virus vaccine leads to lower infant hospitalisation with laboratory‐confirmed RSV disease compared with placebo (high certainty).
1 finding from 1 review
Infant hospitalisation with clinically confirmed RSV disease · pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intrauterine growth restriction · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in intrauterine growth restriction compared with placebo (moderate certainty).
1 finding from 1 review
Stillbirth · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in stillbirth compared with placebo (low certainty).
1 finding from 1 review
Maternal death · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in maternal death compared with placebo (low certainty).
1 finding from 1 review
Preterm birth · pregnant women
It is very uncertain whether respiratory syncytial virus vaccine changes preterm birth compared with placebo (very low certainty).
1 finding from 1 review
Congenital abnormalities · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in congenital abnormalities compared with placebo (high certainty).
1 finding from 1 review
Death before 1 year of age · pregnant women
It is very uncertain whether respiratory syncytial virus vaccine changes infant death compared with placebo (very low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (the number of acute URTIs over a period of time) · children up to the age of 7 at risk of upper respiratory tract infection
Summary of findings table ‐ Vitamin A supplements showed no clear difference in incidence of acute URTIs during the study period (the number of… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (proportion of participants with an acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Adverse events · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Severity of subjective symptoms (mean duration of acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Time to occurrence of acute URTI ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found